Light's Role in Brain Health Paradigm Shift

This week's #MedTechNews highlights six significant milestones across urology, cardiology, diagnostics and others: Aurie announced that the U.S. Food and Drug Administration (FDA) had granted marketing authorization for its Aurie Reusable No-Touch Intermittent Catheter System™ through the Class II De Novo pathway. Biozen announced that the U.S. Food and Drug Administration (FDA) had granted 510(k) clearance to its #BP1000, making it the first cuffless blood pressure device in the United States capable of providing calibration-free, clinically validated spot measurements from the fingertip. PlusOne® announced the expansion of its Wellness Care Collection with the introduction of two purpose-driven lubricants developed to support women through various life stages, including fertility and menopause. TrilliumBiO and Oncobit AG announced the launch of Oncular™, enabling the availability of Oncobit’s uveal melanoma monitoring solution in the United States through TrilliumBiO’s multi-accredited laboratory. Renerva, Inc. announced the implantation of the first patient in its first-in-human clinical study evaluating the Renerva PNM-CAP™ device. SonoClear AS announced the completion of the final clinical procedure in its study assessing the #SonoClearSystem for intracranial ultrasound procedures in patients with neurological tumors. Read the full roundup and discover what's shaping the future of medical technology at: https://lnkd.in/dZcy_A3E #MedicalDevices #HealthcareInnovation #MedTech2026 #CancerDiagnostics #LiquidBiopsy #WomenHealth

Why PRP is gaining a reputation for 'failing' — and why the science says otherwise. In the world of regenerative medicine, Platelet-Rich Plasma (PRP) is often treated as a "commodity." Patients walk into a clinic, ask for a "PRP shot," and expect a standardized result. When it doesn't work, the treatment is labeled a failure. But after years of analyzing clinical outcomes, the truth is more nuanced. PRP doesn't usually "fail"—the protocol around it does. If you or a patient has seen poor results from biological treatments, it usually comes down to three overlooked variables: 1. The Platelet Dose & Formulation Not all PRP is created equal. There is a massive difference between Leucocyte-Rich (LR) and Leucocyte-Poor (LP) formulations. Using the wrong one for a specific tissue—like a tendon versus a joint space—can lead to inflammation rather than healing. If the concentration isn't verified, you're essentially injecting "expensive water." 2. The 'Seed and Soil' Problem This is the most critical factor I see in my practice. We focus on the "Seed" (the PRP) but ignore the "Soil" (the metabolic environment of the joint). If a patient is in a pro-inflammatory state or has poor metabolic priming, even the highest quality PRP cannot flourish. We must treat the environment, not just the injury. 3. The Precision of Delivery Blind injections are a thing of the past. Without ultrasound guidance, the chance of missing the specific anatomical "sweet spot" is high. In biological care, a miss of even a few millimeters can be the difference between recovery and "failure." We need to move away from the "mechanical" mindset of just "filling a hole" and move toward a biological stewardship of the joint. I’ve just released a deep-dive video into the scientific reasons why these injections fail and how we are restructuring the protocol to ensure biology actually works. Watch the full analysis here: [Insert YouTube Link] I’m interested to hear from other practitioners: Have you found that metabolic priming changes your outcomes with biologicals? #RegenerativeMedicine #Orthopaedics #PRP #MedicalInnovation #JointHealth #BiologyFirst #EvidenceBasedMedicine

A Second Chance Deserves the Right Protection In the world of organ transplantation, success doesn’t end in the operating room—it truly begins there. For every transplant recipient, life after surgery is a delicate balance. At the heart of this balance lies Narrow Therapeutic Index (NTI) drugs like Tacrolimus—where even the smallest variation in drug levels can make a meaningful difference between graft survival and rejection. Tacrolimus is not just another medication. It is a lifeline. 🔹 Too little exposure may lead to rejection 🔹 Too much can increase the risk of toxicity 🔹 Even minor variability can impact long-term outcomes This is why consistency, quality, and reliability in therapy remain so critical. When we talk about giving patients a second chance at life, the shared focus is always on protecting that second chance—through thoughtful decisions and sustained care. Choosing the right quality medication is not just a clinical step—it is a commitment to: ✔️ Stability in drug exposure ✔️ Predictable outcomes ✔️ Long-term graft survival ✔️ Patient safety and confidence For transplant recipients, every dose matters. Every day matters. As healthcare professionals, our role goes beyond enabling access—we contribute to ensuring that every therapy supports precision, trust, and continuity of care. Because a second life is not only given—it is carefully protected, every single day. #TransplantCare #Tacrolimus #NTIDrugs #PatientSafety #SecondChance #HealthcareExcellence #Immunosuppression

FDA recommends stopping SGLT2 inhibitors 3-4 days before any surgery. But should every patient be managed the same way? A new multidisciplinary consensus statement led by the SOCIETY FOR PERIOPERATIVE ASSESSMENT AND QUALITY IMPROVEMENT (SPAQI), published in the British Journal of Anesthesia and co-authored by EGDRC’s Guillermo Umpierrez, MD, provides updated recommendations for perioperative SGLT2 inhibitor management. Key takeaways:  1. Current multisociety guidelines vary significantly on when to stop SGLT2 inhibitors, how to monitor patients, and how to prevent #euglycemic #diabetic #ketoacidosis  2. The SPAQI consensus moves away from a one-size-fits-all approach, recommending tailored management based on diabetes diagnosis, comorbidities, and surgical and dietary considerations  3. Updated monitoring and prevention strategies for euglycemic diabetic ketoacidosis are included, informed by a systematic review and modified Delphi process Read the full consensus statement: https://lnkd.in/eu-hyrv6 Adriana D. Oprea  Basma Mohamed David Hepner Moises A. Deborah Richman Daniel Edmonston Costin Ionescu Mandeep Kumar BobbieJean Sweitzer Emory University Georgia Center for Diabetes Translation Research Yale School of Medicine Duke University Harvard Medical School Cleveland Clinic Lerner College of Medicine Outcomes Research Consortium Stony Brook Medicine Emory University School of Medicine Hartford HealthCare University of Connecticut Vanderbilt University Medical Center Dr. V. Mohan Diabetes Specialist Madras Diabetes Research Foundation International Diabetes Federation AIIMS (All India Institute of Medical Sciences, New Delhi)

Roughly 1% of eligible obese patients have been treated with GLP-1 therapies so far. It feels like everyone is on them. The reality is that real-world penetration is still very limited. I was on a panel at LSI USA '26 last month discussing exactly this. And that number set the tone for everything that followed. Because the more interesting question isn't how many people are on the drug. It's what happens when they stop. In real-world practice, roughly 57% discontinue within 6 months — due to side effects, cost, or both. Most regain weight. And yet some bariatric centers are already reporting procedure volumes down 30%, because patients are losing just enough weight on GLP-1 that they no longer qualify for major surgery. The system is reorganizing around a drug that most eligible patients haven't even tried yet. Meanwhile, early publications are examining what happens when patients start on GLP-1, reduce their dose over time, and are then referred for a minimally invasive procedure like ESG. Initial data suggest the combination may offer weight loss and durability comparable to surgery, at substantially lower burden. The question has shifted — from which intervention to how they work together. Thanks to Emmy Jedras for moderating, and to the audience members who pushed the conversation in the right directions. LSI  LSI USA #LSIUSA2026 #ObesityCare 𝘌𝘯𝘥𝘰𝘡𝘪𝘱™ 𝘪𝘴 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥 𝘢𝘯𝘥 𝘢𝘱𝘱𝘳𝘰𝘷𝘦𝘥 𝘧𝘰𝘳 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘶𝘴𝘦 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦. 𝘐𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴, 𝘌𝘯𝘥𝘰𝘡𝘪𝘱™ 𝘪𝘴 𝘢𝘯 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦 𝘢𝘯𝘥 𝘪𝘴 𝘭𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘰𝘳 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦. 𝘚𝘵𝘢𝘵𝘦𝘮𝘦𝘯𝘵𝘴 𝘳𝘦𝘨𝘢𝘳𝘥𝘪𝘯𝘨 𝘌𝘚𝘎 𝘢𝘳𝘦 𝘣𝘢𝘴𝘦𝘥 𝘰𝘯 𝘱𝘶𝘣𝘭𝘪𝘴𝘩𝘦𝘥 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘭𝘪𝘵𝘦𝘳𝘢𝘵𝘶𝘳𝘦.

Type 2 Diabetes affects more than half a billion people globally, and that number continues to rise. For decades, care has largely centered on two options: → Lifelong medications, which can be effective but often require ongoing escalation, carry cost burdens, and rarely address underlying metabolic dysfunction. → Invasive bariatric surgery, which can deliver a durable metabolic impact but is accessible only to a small fraction of eligible patients. Both matter. Both have an important place in care. But in a disease this large and complex, it is worth asking whether those two paths, alone, will be enough for the scale of unmet need over the next decade. That is the opening for a third conversation: endoscopic metabolic restoration. As understanding of gut-driven metabolic signaling continues to advance, a procedural category is beginning to emerge between chronic medication escalation and invasive surgery. One that may eventually sit within outpatient, minimally invasive endoscopic care. At Aqua Medical, this is the category we are working to help build: a through-the-scope technology, investigational and designed with the realities of clinical practice in mind. Category change in medicine is slow. But in a disease as prevalent as Type 2 Diabetes, even modest expansions of the treatment pathway can matter. Clinically and economically. The RFVA system is FDA-cleared for marketing for its cleared indications. Use of the RFVA system for the PIMA procedure is investigational. The safety and effectiveness of the RFVA system for the PIMA procedure have not yet been established. #Type2Diabetes #MetabolicHealth #Endoscopy #MedTech #AquaMedical

Hip pain associated with labral pathology is often approached with short-term solutions, anti-inflammatories, activity modification, or corticosteroid injections. While these may reduce symptoms, they do not address underlying tissue integrity. This is where regenerative medicine, specifically Platelet-Rich Plasma (PRP), is changing the treatment conversation. PRP introduces concentrated growth factors directly into compromised tissue, supporting cellular repair, collagen production, and improved joint function. When applied appropriately, it can play a meaningful role in delaying or avoiding surgical intervention, particularly in active patients and those with early to moderate degeneration. At Desert Spine and Sports Physicians, our board-certified, fellowship-trained physiatrists and pain management physicians integrate PRP within a broader, diagnostic-first care model, ensuring treatment selection is driven by precise evaluation, not protocol. For clinicians and patients alike, the question is no longer just how to reduce pain, but how to restore function. Read the full guide: PRP for Hip Pain & Labral Tears: https://lnkd.in/gN2pjSQU #RegenerativeMedicine #MusculoskeletalCare#NonSurgicalCare #DesertSpineAndSportsPhysicians

Sclerotherapy remains the first-line treatment for spider veins in most international guidelines and consensus documents. However, every phlebologist has encountered those particularly resistant telangiectasias: fine residual vessels that persist despite technically successful sclerotherapy. In these cases, an interesting complementary strategy is what could be described as laser after sclerotherapy — the use of transdermal laser as an adjunctive tool for treating residual or refractory spider veins following sclerotherapy. In my experience, one device that offers several practical advantages for this approach is the Blue Laser by ORLIGHT. Beyond its portability and ease of use in daily practice, it also represents a relatively affordable option for physicians compared with larger and more complex laser platforms. According to publicly available manufacturer information, the device has also received FDA clearance for specific dermatologic and vascular indications. More importantly, the real challenge is not the device itself, but proper patient selection, understanding the underlying venous pathophysiology, and integrating different treatment modalities in a rational and evidence-based way. Perhaps the future of aesthetic venous treatment will not depend on defending a single technique, but on learning how to combine sclerotherapy, laser technology, and hemodynamic management into increasingly personalized strategies.

𝐓𝐨𝐩 𝐈𝐧𝐭𝐞𝐫𝐯𝐞𝐧𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐚𝐫𝐝𝐢𝐨𝐥𝐨𝐠𝐲 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐇𝐞𝐚𝐫𝐭 𝐂𝐚𝐫𝐞 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲: https://lnkd.in/gnEYq-B8 Interventional cardiology continues to evolve with advanced medical devices that improve the diagnosis and treatment of cardiovascular diseases. Leading companies such as Boston Scientific Corporation, Medtronic, Abbott Laboratories, and Edwards Lifesciences are driving innovation in stents, catheters, and minimally invasive cardiac procedures. These organizations, along with global players like Terumo Corporation, Philips, and Meril Life Sciences, are helping shape the future of cardiovascular treatment through cutting-edge technologies and life-saving solutions. The global interventional cardiology devices market, valued at USD 29.41 billion in 2025, stood at USD 31.12 billion in 2026 and is projected to advance at a resilient CAGR of 6.4% from 2026 to 2031, culminating in a forecasted valuation of USD 42.39 billion by the end of the period. By the angioplasty stent market, the drug-eluting stents segment is expected to register the highest CAGR of 7.6% during the forecast period. By the structural heart devices market, the other therapy devices segment is expected to dominate the market, with a share of 57.3% in 2025.